タナカ ジユンジ
TANAKA Junji
田中 淳司 所属 その他 その他 職種 非常勤嘱託 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. |
掲載誌名 | 正式名:Bone marrow transplantation 略 称:Bone Marrow Transplant ISSNコード:14765365/02683369 |
掲載区分 | 国外 |
巻・号・頁 | 56(11),pp.2842-2848 |
著者・共著者 | Akahoshi Yu†, Arai Yasuyuki, Nishiwaki Satoshi, Tachibana Takayoshi, Shinohara Akihito, Doki Noriko, Uchida Naoyuki, Tanaka Masatsugu, Kanda Yoshinobu, Shiratori Souichi, Ozawa Yukiyasu, Shono Katsuhiro, Katayama Yuta, Tanaka Junji, Fukuda Takahiro, Atsuta Yoshiko, Kako Shinichi |
発行年月 | 2021/11 |
概要 | White blood cell count (WBC) at diagnosis is the conventional prognostic factor in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nevertheless, little is known about the impact of WBC at diagnosis considering the minimal residual disease (MRD) status at allogeneic hematopoietic cell transplantation (HCT). We evaluated adult patients with Ph+ ALL who achieved negative-MRD and received HCT in first complete remission between 2006 and 2018. The entire cohort was temporally divided into derivation (n = 258) and validation cohorts (n = 366). Using a threshold of 15,000/μL, which was determined by a receiver operating characteristic curve analysis in the derivation cohort, high WBC was associated with an increased risk of hematological relapse in both the derivation cohort (25.3% vs. 11.6% at 7 years, P = 0.004) and the validation cohort (16.2% vs. 8.5% at 3 years, P = 0.025). In multivariate analyses, high WBC was a strong predictor of hematological relapse in the derivation cohort (HR, 2.52, 95%CI 1.32-4.80, P = 0.005) and in the validation cohort (HR, 2.32, 95%CI, 1.18-4.55; P = 0.015). In conclusion, WBC at diagnosis with a new threshold of 15,000/μL should contribute to better risk stratification in patients with negative-MRD at HCT. |
DOI | 10.1038/s41409-021-01422-7 |
PMID | 34331021 |